427 related articles for article (PubMed ID: 11927189)
1. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.
Capuron L; Gumnick JF; Musselman DL; Lawson DH; Reemsnyder A; Nemeroff CB; Miller AH
Neuropsychopharmacology; 2002 May; 26(5):643-52. PubMed ID: 11927189
[TBL] [Abstract][Full Text] [Related]
2. Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine.
McNutt MD; Liu S; Manatunga A; Royster EB; Raison CL; Woolwine BJ; Demetrashvili MF; Miller AH; Musselman DL
Neuropsychopharmacology; 2012 May; 37(6):1444-54. PubMed ID: 22353759
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment.
Capuron L; Neurauter G; Musselman DL; Lawson DH; Nemeroff CB; Fuchs D; Miller AH
Biol Psychiatry; 2003 Nov; 54(9):906-14. PubMed ID: 14573318
[TBL] [Abstract][Full Text] [Related]
4. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
5. Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman DL; Lawson DH; Gumnick JF; Manatunga AK; Penna S; Goodkin RS; Greiner K; Nemeroff CB; Miller AH
N Engl J Med; 2001 Mar; 344(13):961-6. PubMed ID: 11274622
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychiatric adverse effects of interferon-alpha: recognition and management.
Raison CL; Demetrashvili M; Capuron L; Miller AH
CNS Drugs; 2005; 19(2):105-23. PubMed ID: 15697325
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C.
Raison CL; Woolwine BJ; Demetrashvili MF; Borisov AS; Weinreib R; Staab JP; Zajecka JM; Bruno CJ; Henderson MA; Reinus JF; Evans DL; Asnis GM; Miller AH
Aliment Pharmacol Ther; 2007 May; 25(10):1163-74. PubMed ID: 17451562
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma.
Friebe A; Schwarz MJ; Schmid-Wendtner M; Volkenandt M; Schmidt F; Horn M; Janssen G; Schaefer M
J Immunother; 2007 Apr; 30(3):333-7. PubMed ID: 17414324
[TBL] [Abstract][Full Text] [Related]
10. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
Baldwin D; Bridgman K; Buis C
J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
[TBL] [Abstract][Full Text] [Related]
11. Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy.
Auyeung SF; Long Q; Royster EB; Murthy S; McNutt MD; Lawson D; Miller A; Manatunga A; Musselman DL
Clin Trials; 2009 Oct; 6(5):480-90. PubMed ID: 19786415
[TBL] [Abstract][Full Text] [Related]
12. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial.
Heinze S; Egberts F; Rötzer S; Volkenandt M; Tilgen W; Linse R; Boettjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Hinzpeter A; Hauschild A; Schaefer M
J Immunother; 2010 Jan; 33(1):106-14. PubMed ID: 19952950
[TBL] [Abstract][Full Text] [Related]
13. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.
Roscoe JA; Morrow GR; Hickok JT; Mustian KM; Griggs JJ; Matteson SE; Bushunow P; Qazi R; Smith B
Breast Cancer Res Treat; 2005 Feb; 89(3):243-9. PubMed ID: 15754122
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes.
Greenberg DB; Jonasch E; Gadd MA; Ryan BF; Everett JR; Sober AJ; Mihm MA; Tanabe KK; Ott M; Haluska FG
Cancer; 2000 Jul; 89(2):356-62. PubMed ID: 10918166
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
Chaudhry HR; Qureshi Z; Tareen IA; Yazdani I
J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
[TBL] [Abstract][Full Text] [Related]
16. Can antidepressants prevent interferon-alpha-induced depression? A review of the literature.
Galvão-de Almeida A; Guindalini C; Batista-Neves S; de Oliveira IR; Miranda-Scippa A; Quarantini LC
Gen Hosp Psychiatry; 2010; 32(4):401-5. PubMed ID: 20633744
[TBL] [Abstract][Full Text] [Related]
17. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
Baldwin DS; Hawley CJ; Abed RT; Maragakis BP; Cox J; Buckingham SA; Pover GH; Ascher A
J Clin Psychiatry; 1996; 57 Suppl 2():46-52. PubMed ID: 8626363
[TBL] [Abstract][Full Text] [Related]
18. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms.
Maddock C; Baita A; Orrù MG; Sitzia R; Costa A; Muntoni E; Farci MG; Carpiniello B; Pariante CM
J Psychopharmacol; 2004 Mar; 18(1):41-6. PubMed ID: 15107183
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL; Weisler RH; Chang W; Olausson B; Paulsson B; Brecher M; Agambaram V; Merideth C; Nordenhem A; Young AH;
J Clin Psychiatry; 2010 Feb; 71(2):163-74. PubMed ID: 20122366
[TBL] [Abstract][Full Text] [Related]
20. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
